Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Successful explantation of a corneal microlens for presbyopia and implantation of a trifocal IOL in a patient who developed ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

The new approvals are the latest in Johnson & Johnson’s IOLs; the Company claims the new TECNIS Eyhance IOL can slightly extend the depth of focus and deliver better image contrast. The Food and Drug ...

SpyGlass Pharma Inc., which is promising an intraocular lens that will reshape the treatment of glaucoma, emerged from its initial public offering last month with a big boost from Wall Street.

Dr. Greenstein answers the question: 'Types Of Intraocular Lens Implants?' Aug. 24, 2009— -- Question: What are the different types of intraocular lens implants and how do I decide on which one ...

ReportsnReports.com adds the global intraocular lens (IOL) market is projected to reach USD 4.56 Billion by 2022 from USD 3.50 Billion in 2017, at a CAGR of 5.4%. The growth of this market is majorly ...